ReviewFrontiers in medicine2025
Personalized peripheral vascular interventional embolization for tumor: tailoring treatment to improve outcomes.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors pose a significant global health burden, necessitating innovative treatment approaches. Personalized peripheral vascular interventional embolization emerges as a promising strategy to enhance outcomes in tumor therapy. This review consolidates evidence on the principles, influencing factors, implementation processes, and clinical applications of this approach. By analyzing tumor vascular anatomy and biological behavior, along with patient-specific factors, clinicians can tailor embolization techniques and materials to maximize efficacy and minimize complications. In practical clinical settings, personalized embolization has shown remarkable potential to enhance patient outcomes. For instance, in patients with hepatocellular carcinoma, personalized chemoembolization not only significantly improved survival rates but also reduced post-procedure complications, thereby improving quality of life. Similarly, in colorectal cancer liver metastases, the combination of embolization with anti-angiogenic agents has proven effective in controlling disease progression, offering a new therapeutic option where conventional treatments fall short. Despite challenges such as technical complexity and treatment costs, advancements in imaging technology, genomics, and novel embolic agent development offer substantial opportunities to refine and expand the application of personalized interventional embolization, potentially transforming the landscape of cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.